159 - Innovations in Crystallization Techniques for Active Pharmaceutical Ingredients (S11E9)

Welcome to the deep dive. Today we're tackling
something pretty foundational in medicine. Yeah,
what's in the agenda? how the active ingredients
in our drugs, the APIs, actually form into crystals.
Ah, crystallization, okay. We're looking at some
of the newer, more innovative ways scientists
are approaching this. It's a really crucial process.
It absolutely is. We've gathered some insights
on the key advancements. The goal really is to
see how these innovations are making things more
efficient, more controllable. And scalable, right,
for actually producing the medicines people need.
Exactly, better processes for better medicines,
essentially. Okay, so let's start maybe with
the basics, but with that pharmaceutical twist.
Yeah. It's not just what the API molecule is.
Right. It's how it's put together, the structure.
We've talked about polymorphism before, haven't
we? Yeah. That idea that the same molecule can
pack in different ways. We have. And it's quite
fascinating, isn't it? One single chemical compound.
Your API. Can arrange itself into multiple distinct
crystal structures. Yeah. Like building different
things with the same LEGO bricks. And those different
structures, the polymorphs, they behave differently
in the body. Oh, drastically. It impacts things
like how easily the drug dissolves, how well
it gets absorbed. It's bioavailability. Exactly.
So getting the right structure is critical for
effectiveness and for safety, too. So the whole
crystallization process isn't just about making
the solid. It's about making the right solid
form. consistently. You've nailed it. And that
need for tight control is pushing innovation
in how we manufacture these things. Which leads
us to continuous crystallization. Precisely.
That's a big shift we're seeing. Continuous processing.
So moving away from doing things in big separate
batches. Yeah, the traditional batch method.
Continuous crystallization offers some real advantages.
Like what? What makes it better? Well, think
about batch processing. You start it, you run
it, you stop it. then you start again. There's
inherent variability just in those stops and
starts. With continuous, it's an ongoing flow,
a steady state. Ah, so you can keep conditions
more constant. Exactly. You get much finer, more
consistent control over critical things like
temperature, concentration, mixing all throughout
the process. Which should lead to a more uniform
product batch after batch. Yeah. Or rather, just
a continuous stream of uniform product. That's
the idea. Greater consistency. And we know from
developing dosage forms that consistency is paramount.
Yeah, for ensuring a reliable supply to patients.
Makes sense. Absolutely. Consistent manufacturing
means consistent therapy. It minimizes that batch
to batch variability. OK, so that's the big picture
process shift. Yeah. What about drilling down
a bit? Particle size keeps coming up. Oh, it's
incredibly important. Seems like a small detail,
but. But it has a huge effect. It really does.
Think about how a drug dissolves. The size of
the crystal particles directly influences the
rate. Right, like powdered sugar dissolving faster
than a sugar cube. Perfect analogy. Smaller API
crystals generally mean more surface area exposed
to body fluids. So they dissolve faster. And
faster dissolution usually means faster absorption,
faster onset of action. And we saw, I think when
we looked at lipid crystallization, that things
like cooling rate can really dictate that final
size. Exactly. Cooling rate is a big one, but
also mixing speed, the presence of additives.
Scientists can manipulate these conditions quite
precisely now. To essentially engineer the crystals
to be the size, maybe even the shape they want.
That's the goal. And because, as you know, dissolution
rate is a key quality control test. Yeah, specified
in regulation. By controlling particle size during
crystallization, you're directly influencing
that performance metric, ensuring a more predictable
therapeutic effect. It's really about control
in multiple levels, then. Fascinating. Now, another
area you mentioned was salt formation. Yes, particularly
focusing on things like amine hydrochloride salts,
which are very common. Why turn an API into a
salt in the first place? What's the benefit?
Well, many APIs... in their, let's call it, native
form might not have the best properties for a
medicine. Like poor solubility. Or maybe they
break down easily. Exactly. Poor water solubility
is a big one, makes it hard for the body to absorb.
Or instability, which affects shelf life. Forming
a salt, like an amine hydrochloride, is often
a strategy to significantly improve those properties.
Salts frequently dissolve much better in water.
Which helps with absorption. Right. And they
can also be more chemically stable. Makes for
a more robust drug product. So optimize the API,
but the outline stress developing robust and
scalable salt formation processes. What's the
challenge there? Why is that hard? Well, scaling
any chemical process from a small lab flask to
huge industrial reactors is. Non -trivial there
are always challenges engineering hurdles engineering
chemistry with salt formation The critical thing
is ensuring you consistently get the intended
salt form with high purity Every single time
no matter if you're making a gram or a ton So
avoiding other salt forms or impurities creeping
in precisely and that means you need a really
deep understanding of the underlying science
Yeah, the thermodynamics like which form is most
stable under what conditions and the kinetics
how fast it happens. Yes How fast the salt forms
versus potential side reactions. It requires
very tight control over in conditions temperature,
again, how you mix things, how fast you add reagents.
Sounds quite delicate, actually. It can be. Get
it wrong at scale and you could end up with the
wrong product or a product that doesn't perform
as expected. And again, connecting back, that
ability to make it consistently and reliably
at scale is vital for meeting regulatory standards.
Absolutely. And just ensuring there's enough
drug available for patients. Couldn't be more
critical. Regulators need proof of consistent,
high -quality production. So developing these
robust, scalable processes isn't just good science,
it's a requirement for getting medicines approved
and keeping them on the market. It really seems
like none of this, the continuous processing,
the particle size control, the salt formation,
would be possible without some pretty advanced
ways to, well, see what's going on, analytical
techniques. Oh, absolutely essential. Analytical
science underpins all of this. You need the tools
to monitor the process, and crucially, to characterize
the final API crystals in detail. Like checking
for impurities. Exactly. Techniques like HPLC
high -performance liquid chromatography are workhorses
for that. As we saw in that handbook on impurities,
they can detect and quantify even tiny amounts
of unwanted stuff. Ensuring safety and purity.
Yes. But analytical tools do more than just find
impurities. They also tell you about the physical
form. Uh, back to polymorphism. Making sure you
have the right crystal structure. You got it.
Techniques like X -ray diffraction, various types
of spectroscopy, these let researchers peer into
the crystal lattice, confirm the exact arrangement
of molecules. So they can verify they've made
the correct polymorph, the one with the desired
properties. Precisely. It closes the loop, connecting
the process back to the fundamental solid state
properties of the drug. Okay, so let's recap
a bit. We've covered some really key innovative
areas in API crystallization. We have. It's been
quite a journey from basic principles to advanced
manufacturing. We talked about continuous crystallization
moving towards more efficient, more controlled
production. Right. Aiming for that steady state
and consistency. Then the importance of dialing
in particle size, really engineering those tiny
crystals for optimal drug performance, like dissolution.
Affecting bioavailability directly. And finally,
the challenges and importance of robust, scalable
sol formation. especially for improving API properties
like solubility and stability. Using common examples
like a pentamine hydrochlorides, but the principles
apply broadly. And underpinning it all, the sophisticated
analytical methods needed to monitor, control,
and characterize everything. Absolutely. Can't
do modern pharma development without them. What
really stands out, I think, is that these aren't
just small tweaks. They feel like significant
steps forward. They really are. These advancements
mean we can design and manufacture medicines
that are not only effective, but also consistently
high quality, which is huge for patients globally.
This deep dive, it really brings home how details
that seem microscopic, how molecules packed together,
the exact size of a crystal particle, have such
a profound real -world impact on the medicines
we use every day. It's quite humbling, isn't
it? The level of detail involved. It makes you
appreciate that constant innovation in these
fundamental areas of pharmaceutical science is
just essential. We need it for progress. We absolutely
do. And perhaps a final thought for our listeners.
Next time you take a medication, maybe consider
the incredible journey that API took, the intricate
science like crystallization that ensures it
works safely and effectively. It's a testament
to that relentless drive for better health through
science.